{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:51:27Z","timestamp":1784692287129,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>The hepatitis C virus (HCV) causes chronic and curable disease with a substantial burden of morbidity and mortality across the globe. In the United States (US) and other developed countries, incidence of HCV is increasing and people who inject drugs are disproportionately affected. However, HCV treatment rates amongst patients with substance use disorders (SUD) are suboptimal. In this study, we aimed to understand the perspectives of subspecialist physicians who care for substantial numbers of patients with HCV, including addiction medicine, infectious diseases, and hepatology physicians, to better understand barriers and facilitators of HCV treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We recruited subspecialty physicians via purposive and snowball sampling and conducted semi-structured interviews with 20 physicians at 12 institutions across the US. We used a mixed deductive and inductive approach to perform qualitative content analysis with a rapid matrix technique.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Three major themes emerged: (1) Perceptions of patient complexity; (2) Systemic barriers to care, and (3) Importance of multidisciplinary teams. Within these themes, we elicited subthemes on the effects of patient-level factors, provider-level factors, and insurance-based requirements.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our results suggest that additional strategies are needed to reach the \u201clast mile\u201d untreated patients for HCV care, including decentralization and leverage of telehealth-based interventions to integrate treatment within primary care clinics, SUD treatment facilities, and community harm reduction sites. Such programs are likely to be more successful when multidisciplinary teams including pharmacists and\/or peer navigators are involved. However, burdensome regulatory requirements continue to hinder this expansion in care and should be eliminated.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-024-01057-z","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T05:25:16Z","timestamp":1721885116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Subspecialty physicians\u2019 perspectives on barriers and facilitators of hepatitis C treatment: a qualitative study"],"prefix":"10.1186","volume":"21","author":[{"given":"Erin","family":"Bredenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Callister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Dafoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke Dorsey","family":"Holliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Rowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Calcaterra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,25]]},"reference":[{"issue":"3","key":"1057_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"Polaris Observatory HCV Collaborato","year":"2017","unstructured":"Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161\u201376.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"1057_CR2","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/hep.31756","volume":"74","author":"EW Hall","year":"2021","unstructured":"Hall EW, Schillie S, Vaughan AS, Jones J, Bradley H, Lopman B, et al. County-Level Variation in Hepatitis C Virus Mortality and trends in the United States, 2005\u20132017. Hepatology. 2021;74(2):582\u201390.","journal-title":"Hepatology"},{"issue":"5","key":"1057_CR3","doi-asserted-by":"publisher","first-page":"949","DOI":"10.2105\/AJPH.2020.306149","volume":"111","author":"D Holtzman","year":"2021","unstructured":"Holtzman D, Asher AK, Schillie S. The Changing Epidemiology of Hepatitis C Virus Infection in the United States during the years 2010 to 2018. Am J Public Health. 2021;111(5):949\u201355.","journal-title":"Am J Public Health"},{"issue":"4","key":"1057_CR4","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/MEG.0000000000002498","volume":"35","author":"DU Lee","year":"2023","unstructured":"Lee DU, Ponder R, Lee KJ, Yoo A, Fan GH, Jung D, et al. The nationwide trends in hospital admissions, deaths, and costs related to Hepatitis C stratified by psychiatric disorders and substance use: an analysis of US hospitals between 2016 and 2019. Eur J Gastroenterol Hepatol. 2023;35(4):402\u201319.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1057_CR5","doi-asserted-by":"publisher","first-page":"103469","DOI":"10.1016\/j.drugpo.2021.103469","volume":"96","author":"J Grebely","year":"2021","unstructured":"Grebely J, Collins AB, Artenie AA, Sutherland R, Meyer JP, Barocas JA, et al. Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs. Int J Drug Policy. 2021;96:103469.","journal-title":"Int J Drug Policy"},{"key":"1057_CR6","unstructured":"Bhattacharya D, Aronsohn A, Price J, Lo Re V, Hepatitis C. Guidance 2023 Update: AASLD-IDSA recommendations for Testing, Managing, and treating Hepatitis C virus infection. Clin Infect Dis. 2023."},{"key":"1057_CR7","doi-asserted-by":"crossref","unstructured":"Tandan M, Dunlea S, Bury G, Hepatitis C. Infection and treatment among injecting drug users attending General Practice: a systematic review and Meta-analysis. Int J Environ Res Public Health. 2023;20(8).","DOI":"10.3390\/ijerph20085569"},{"key":"1057_CR8","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis 2016\u20132021: Towards ending viral hepatitis. 2016."},{"issue":"1","key":"1057_CR9","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1186\/s12889-023-16017-8","volume":"23","author":"CR Balsom","year":"2023","unstructured":"Balsom CR, Farrell A, Kelly DV. Barriers and enablers to testing for hepatitis C virus infection in people who inject drugs - a scoping review of the qualitative evidence. BMC Public Health. 2023;23(1):1038.","journal-title":"BMC Public Health"},{"key":"1057_CR10","doi-asserted-by":"publisher","first-page":"107705","DOI":"10.1016\/j.drugalcdep.2019.107705","volume":"206","author":"AD Marshall","year":"2020","unstructured":"Marshall AD, Grebely J, Dore GJ, Treloar C. Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists-the practitioner experience. Drug Alcohol Depend. 2020;206:107705.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"1057_CR11","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1177\/15248399231169928","volume":"24","author":"E DiDomizio","year":"2023","unstructured":"DiDomizio E, Chandra DK, Nichols L, Villanueva M, Altice FL. Challenges to Achieving HCV Micro-elimination in People with HIV in the United States: provider perspectives and the role of Implicit Bias. Health Promot Pract. 2023;24(5):998\u20131008.","journal-title":"Health Promot Pract"},{"key":"1057_CR12","doi-asserted-by":"publisher","first-page":"103247","DOI":"10.1016\/j.drugpo.2021.103247","volume":"96","author":"A Amoako","year":"2021","unstructured":"Amoako A, Ortiz-Paredes D, Engler K, Lebouch\u00e9 B, Klein MB. Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: a knowledge synthesis. Int J Drug Policy. 2021;96:103247.","journal-title":"Int J Drug Policy"},{"issue":"6","key":"1057_CR13","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1093\/tbm\/ibz085","volume":"9","author":"MS McCreight","year":"2019","unstructured":"McCreight MS, Rabin BA, Glasgow RE, Ayele RA, Leonard CA, Gilmartin HM, et al. Using the practical, robust implementation and sustainability model (PRISM) to qualitatively assess multilevel contextual factors to help plan, implement, evaluate, and disseminate health services programs. Transl Behav Med. 2019;9(6):1002\u201311.","journal-title":"Transl Behav Med"},{"issue":"7\u20138","key":"1057_CR14","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S0277-9536(99)00350-0","volume":"50","author":"S Curtis","year":"2000","unstructured":"Curtis S, Gesler W, Smith G, Washburn S. Approaches to sampling and case selection in qualitative research: examples in the geography of health. Soc Sci Med. 2000;50(7\u20138):1001\u201314.","journal-title":"Soc Sci Med"},{"issue":"1","key":"1057_CR15","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12874-016-0242-z","volume":"16","author":"MA Valerio","year":"2016","unstructured":"Valerio MA, Rodriguez N, Winkler P, Lopez J, Dennison M, Liang Y, et al. Comparing two sampling methods to engage hard-to-reach communities in research priority setting. BMC Med Res Methodol. 2016;16(1):146.","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"1057_CR16","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1177\/104973230201200611","volume":"12","author":"JB Averill","year":"2002","unstructured":"Averill JB. Matrix analysis as a complementary analytic strategy in qualitative inquiry. Qual Health Res. 2002;12(6):855\u201366.","journal-title":"Qual Health Res"},{"issue":"10","key":"1057_CR17","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1177\/1049732320921835","volume":"30","author":"C Vindrola-Padros","year":"2020","unstructured":"Vindrola-Padros C, Johnson GA. Rapid Techniques in Qualitative Research: a critical review of the literature. Qual Health Res. 2020;30(10):1596\u2013604.","journal-title":"Qual Health Res"},{"issue":"1","key":"1057_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13012-021-01111-5","volume":"16","author":"AL Nevedal","year":"2021","unstructured":"Nevedal AL, Reardon CM, Opra Widerquist MA, Jackson GL, Cutrona SL, White BS, et al. Rapid versus traditional qualitative analysis using the Consolidated Framework for Implementation Research (CFIR). Implement Sci. 2021;16(1):67.","journal-title":"Implement Sci"},{"issue":"1","key":"1057_CR19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1365-2648.2007.04569.x","volume":"62","author":"S Elo","year":"2008","unstructured":"Elo S, Kyng\u00e4s H. The qualitative content analysis process. J Adv Nurs. 2008;62(1):107\u201315.","journal-title":"J Adv Nurs"},{"issue":"3","key":"1057_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.afjem.2017.08.001","volume":"7","author":"C Erlingsson","year":"2017","unstructured":"Erlingsson C, Brysiewicz P. A hands-on guide to doing content analysis. Afr J Emerg Med. 2017;7(3):93\u20139.","journal-title":"Afr J Emerg Med"},{"issue":"4","key":"1057_CR21","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.1016\/S2214-109X(20)30505-2","volume":"9","author":"E Oru","year":"2021","unstructured":"Oru E, Trickey A, Shirali R, Kanters S, Easterbrook P. Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis. Lancet Glob Health. 2021;9(4):e431\u201345.","journal-title":"Lancet Glob Health"},{"issue":"3","key":"1057_CR22","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3122\/jabfm.2019.03.180286","volume":"32","author":"GM Simoncini","year":"2019","unstructured":"Simoncini GM, Koren DE. Hepatitis C update and expanding the role of primary care. J Am Board Fam Med. 2019;32(3):428\u201330.","journal-title":"J Am Board Fam Med"},{"issue":"10","key":"1057_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/01.JAA.0000873784.48761.b2","volume":"35","author":"R Alberts","year":"2022","unstructured":"Alberts R, Zimmermann A, Martinez A. Improving hepatitis C screening and access to treatment. Jaapa. 2022;35(10):17\u201321.","journal-title":"Jaapa"},{"issue":"2","key":"1057_CR24","doi-asserted-by":"publisher","first-page":"e0229143","DOI":"10.1371\/journal.pone.0229143","volume":"15","author":"R Castro","year":"2020","unstructured":"Castro R, Perazzo H, de Araujo L, Gutierres IG, Grinsztejn B, Veloso VG. Effectiveness of implementing a decentralized delivery of hepatitis C virus treatment with direct-acting antivirals: a systematic review with meta-analysis. PLoS ONE. 2020;15(2):e0229143.","journal-title":"PLoS ONE"},{"issue":"15","key":"1057_CR25","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1007\/s11606-023-08386-y","volume":"38","author":"LM McCrary","year":"2023","unstructured":"McCrary LM, Roberts KE, Bowman MC, Castillo B, Darling JM, Dunn C, et al. Inpatient Hepatitis C Treatment Coordination and initiation for patients who inject drugs. J Gen Intern Med. 2023;38(15):3428\u201333.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"1057_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40352-022-00191-9","volume":"10","author":"KF Kamis","year":"2022","unstructured":"Kamis KF, Wyles DL, Minturn MS, Scott T, McEwen D, Hurley H, et al. A retrospective, descriptive study of hepatitis C testing, prevalence, and care continuum among adults on probation. Health Justice. 2022;10(1):26.","journal-title":"Health Justice"},{"key":"1057_CR27","doi-asserted-by":"publisher","first-page":"102738","DOI":"10.1016\/j.drugpo.2020.102738","volume":"88","author":"A Godin","year":"2021","unstructured":"Godin A, Kronfli N, Cox J, Alary M, Maheu-Giroux M. The role of prison-based interventions for hepatitis C virus (HCV) micro-elimination among people who inject drugs in Montr\u00e9al, Canada. Int J Drug Policy. 2021;88:102738.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"1057_CR28","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1353\/hpu.2021.0096","volume":"32","author":"G Kilmer","year":"2021","unstructured":"Kilmer G, Hughes E, Hepatitis B, Hepatitis. C among adults on probation or parole in the United States: 2015\u20132018. J Health Care Poor Underserved. 2021;32(2):671\u20139.","journal-title":"J Health Care Poor Underserved"},{"issue":"10","key":"1057_CR29","doi-asserted-by":"publisher","first-page":"e2338792","DOI":"10.1001\/jamanetworkopen.2023.38792","volume":"6","author":"MD Morris","year":"2023","unstructured":"Morris MD, McDonell C, Luetkemeyer AF, Thawley R, McKinney J, Price JC. Community-based point-of-diagnosis Hepatitis C treatment for marginalized populations: a Nonrandomized Controlled Trial. JAMA Netw Open. 2023;6(10):e2338792.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"1057_CR30","doi-asserted-by":"publisher","first-page":"594","DOI":"10.7326\/M18-1715","volume":"170","author":"MJ Akiyama","year":"2019","unstructured":"Akiyama MJ, Norton BL, Arnsten JH, Agyemang L, Heo M, Litwin AH. Intensive Models of Hepatitis C Care for people who inject drugs receiving opioid agonist therapy: a Randomized Controlled Trial. Ann Intern Med. 2019;170(9):594\u2013603.","journal-title":"Ann Intern Med"},{"issue":"Suppl 5","key":"1057_CR31","doi-asserted-by":"publisher","first-page":"S384","DOI":"10.1093\/infdis\/jiz694","volume":"222","author":"SE Rowan","year":"2020","unstructured":"Rowan SE, Kamis KF, Beum R, Bryan K, Gawenus L, Colon Sanchez D, et al. Viral Hepatitis and Human Immunodeficiency Virus Testing and linkage to care for individuals enrolled in an opioid treatment program. J Infect Dis. 2020;222(Suppl 5):S384\u201391.","journal-title":"J Infect Dis"},{"issue":"12","key":"1057_CR32","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/S2468-1253(22)00275-8","volume":"7","author":"AH Litwin","year":"2022","unstructured":"Litwin AH, Lum PJ, Taylor LE, Mehta SH, Tsui JI, Feinberg J, et al. Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial. Lancet Gastroenterol Hepatol. 2022;7(12):1112\u201327.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"1057_CR33","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/cid\/ciaa111","volume":"71","author":"SA Springer","year":"2020","unstructured":"Springer SA, Del Rio C. Co-located opioid Use Disorder and Hepatitis C Virus treatment is not only right, but it is also the Smart Thing to do as it improves outcomes! Clin Infect Dis. 2020;71(7):1723\u20135.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"1057_CR34","first-page":"Cd012021","volume":"9","author":"L Platt","year":"2017","unstructured":"Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database Syst Rev. 2017;9(9):Cd012021.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"1057_CR35","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1093\/cid\/ciaa105","volume":"71","author":"ES Rosenthal","year":"2020","unstructured":"Rosenthal ES, Silk R, Mathur P, Gross C, Eyasu R, Nussdorf L, et al. Concurrent Initiation of Hepatitis C and Opioid Use Disorder treatment in people who inject drugs. Clin Infect Dis. 2020;71(7):1715\u201322.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1057_CR36","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1080\/10826084.2020.1858106","volume":"56","author":"S Choi","year":"2021","unstructured":"Choi S, Healy S, Shapoval L, Forthal S, Neighbors CJ. Hepatitis C Virus Screening among Medicaid-Insured individuals with opioid Use Disorder across Substance Use Disorder Treatment settings. Subst Use Misuse. 2021;56(2):258\u201363.","journal-title":"Subst Use Misuse"},{"issue":"4","key":"1057_CR37","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s10900-020-00794-z","volume":"45","author":"RK Doshi","year":"2020","unstructured":"Doshi RK, Ruben M, Drezner K, Lachmann A, Kuo I, Chanes-Mora P, et al. Knowledge, attitudes, and behaviors related to Hepatitis C Screening and Treatment among Health Care Providers in Washington, DC. J Community Health. 2020;45(4):785\u201394.","journal-title":"J Community Health"},{"issue":"5","key":"1057_CR38","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/jvh.13807","volume":"30","author":"NA Terrault","year":"2023","unstructured":"Terrault NA, Slepin J, Kanner R, Gailloux K, Catalli L, McKinney J, et al. Strategies to increase primary care provider capacity for hepatitis C care: the California ECHO-PLUS study. J Viral Hepat. 2023;30(5):397\u2013405.","journal-title":"J Viral Hepat"},{"issue":"16","key":"1057_CR39","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1001\/jama.2024.2452","volume":"331","author":"AH Talal","year":"2024","unstructured":"Talal AH, Markatou M, Liu A, Perumalswami PV, Dinani AM, Tobin JN, et al. Integrated Hepatitis C-Opioid Use Disorder Care through facilitated telemedicine: a Randomized Trial. JAMA. 2024;331(16):1369\u201378.","journal-title":"JAMA"},{"key":"1057_CR40","doi-asserted-by":"publisher","first-page":"103917","DOI":"10.1016\/j.drugpo.2022.103917","volume":"111","author":"EB Cunningham","year":"2023","unstructured":"Cunningham EB, Wheeler A, Hajarizadeh B, French CE, Roche R, Marshall AD, et al. Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: a systematic review and meta-analysis. Int J Drug Policy. 2023;111:103917.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"1057_CR41","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1177\/0033354918772059","volume":"133","author":"JL Marcus","year":"2018","unstructured":"Marcus JL, Hurley LB, Chamberland S, Champsi JH, Gittleman LC, Korn DG, et al. Disparities in initiation of Direct-Acting Antiviral agents for Hepatitis C virus infection in an Insured Population. Public Health Rep. 2018;133(4):452\u201360.","journal-title":"Public Health Rep"},{"issue":"1","key":"1057_CR42","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12954-021-00516-1","volume":"18","author":"S Goutzamanis","year":"2021","unstructured":"Goutzamanis S, Horyniak D, Doyle JS, Hellard M, Higgs P. Perceived physical health outcomes of direct-acting antiviral treatment for hepatitis C: a qualitative study. Harm Reduct J. 2021;18(1):73.","journal-title":"Harm Reduct J"},{"key":"1057_CR43","unstructured":"National Viral Hepatitis Roundtable, Center for health law and policy innovation. Harvard law school. Hepatitis C: The state of medicaid access 2017 National Summary Report. 2017."},{"key":"1057_CR44","unstructured":"National Viral Hepatitis Roundtable, Center for health law and policy innovation. Harvard law school. 2024 National Snapshot Report. 2024."}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01057-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-01057-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01057-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T05:35:09Z","timestamp":1721885709000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-01057-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,25]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1057"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-01057-z","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,25]]},"assertion":[{"value":"20 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed by the Colorado Multiple Institutional Review Board (COMIRB #22-1839) and found to be exempt. All participants were informed of the risks and benefits of participation and consented to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"140"}}